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the only OARs to be significantly affected by applying these 
moves and in these cases no clinically significant deviations 
were observed. 
Conclusions: Variations in the factors investigated, do not 
correlate with tumour motion within DIBH. The diaphragm is 
not stable within BH. Applying soft tissue moves is safe to 
surrounding OARs once due clinical attention is paid to close 
critical structures. 
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Purpose/Objective: This work evaluated the inter-observer 
variability in CBCT registration for prostate patients treated 
with IMRT (Intensity Modulated Radiation Therapy). We also 
demonstrated the importance of daily CBCT registration for 
this treatment. 
Materials and Methods: In the first study VMAT plans were 
produced for 2 prostate cancer patients and a voluntary shift 
of the isocenter was introduced in the anterior/posterior 
direction. A total of 22 different VMAT plans were evaluated 
with 13 plans for the first patient and 9 plans for the second. 
In the second study, 12 technologists each registered 22 CBCT 
for 22 different prostate patients. Medical doctors have done 
the same registrations that was considered as the Gold 
Standard reference. Registration was done using bony 
anatomy and adjustments made on by the user on evaluation 
of the rectum and prostate. Shifts in all three axis were 
documented for a total of 286 CBCT. Two statistical methods 
were used to analyse the results. The first was the 95 
percentile to calculate the minimum threshold under which 
the users found similar values. The second was the ANOVA 
test, followed by the Post-Hoc/Bonferroni test. These tests 
were used to find differences in inter-observer registration 
variability and determine whether any individual users 
performed registrations which differed significantly from 
those of the other users. 
Results: The dosimetric study showed that a shift of 5 mm in 
the posterior direction was enough to deliver a higher dose 
than acceptable to the rectum in both cases.A different 
threshold was found by shifting anteriorly, ranging from 5 
mm for patient B to 12 mm for patient A. On the other hand, 
the statistical analysis of the registration study showed that 
using the 95 percentile, threshold values were demonstrated 
of 2.1, 3.5 and 7.3 mm in the left/right, target/gun and 
anterior/posterior respectively. The Anova test showed a low 
p-value in the target/gun axis but using the Post-Hoc analysis 
there were no significant differences between the 
technologists and the medical doctors. 
Conclusions: This study showed the importance of a daily 
CBCT/CT registration in prostate radiation treatment. The 
different studies also showed that partial delegation of the 
prostate registration fto the technologists is feasible under 
some security thresholds. However, regular training and 
evaluation should be done by the medical doctors and 
physicists. 
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Purpose/Objective: A higher awareness of changing anatomy 
has resulted in an increased complexity and a continuous 
change of the image guided radiotherapy (IGRT) process. To 
guarantee the quality of this process we developed a quality 
assurance (QA) program which involves 1) Inspection of the 
clinical IGRT process; 2)A check to assess if certain structural 
abnormalities occur in specific patient groups. This study 
describes the methodology of our QA program and the results 
after the first 8 months. 
Materials and Methods: Each member of the IGRT group 
performed QA tasks once a week for 4 hours. A checklist was 
used to assess whether the IGRT process was performed 
according to protocol and to verify whether there were other 
abnormalities present. This checklist was developed within 
an interdisciplinary group discussion. Results of the QA 
program were documented in an in-house developed 
computer program. 
The following items were monitored:1)The number of errors 
in the IGRT preparation and execution process. 2)Anatomical 
and other potential dose altering changes that occurred 
during treatment. Monthly, results were discussed with the 
members of the IGRT group and, if necessary, feedback is 
given to the department. After the first 8 months, all QA 
findings were presented on a departmental level. 
Results: In an 8 month period 5 dedicated RTTs, all IGRT 
working group members, reviewed 154 patients with a total 
of 609 CBCTs, including breast, lung, rectum, oesophagus, 
gynaecological, bladder and central nervous system patients.  
•In 12% of the patients (n=43) anatomical changes were 
found, mainly in patients treated for lung or oesophagus 
cancer. 3% of the whole reviewed population needed 
replanning during treatment.  
•7.2 % of the patients showed a change in body contour 
larger than 1 cm because of weight difference or seroma 
change.  
•17% of the patients showed irregularities in the IGRT 
preparation process. E.g. registration areas, defining the 
correct clipbox, correction reference point or match 
algorithm, were not defined according to protocol. 
These figures gave us a better insight regarding the IGRT 
process.  
•In 3% of all the CBCTs rotation values were more than 4 
degrees (the upper limit for acceptable rotations) the 
majority (77%) around the left-right axis.  
•In 1.6% of the CBCTs a part of the CTV was outside the 
PTV as a result of tumor progression, tumor shift, or 
changes in seroma.  
•5 patients showed undetected lesions in the lung. In 2 
patients after further examination these proved to be 
malignant. 
Conclusions: The results of the QA program indicates that a 
substantial part of the treated population show changes 
which potentially alter dose delivery. In 3% of the 
investigated population rescanning and replanning was 
considered necessary. 
